Episode Details

Adult palatal expansion is having a moment — but how much of MARPE is actually skeletal, and how safe is it in a thirty-year-old? This episode walks through the evidence: a 93.87% success rate graded "very low," a 49% basal bone share, and a case series of midface fractures tied to rapid activation. Then the other end of the spectrum: tirzepatide (Zepbound) becoming the first FDA-approved drug for OSA, and what that means for the dentists fitting mandibular advancement devices. Plus the trial to watch — NCT07734688 at the University of Malaya — and whether deep learning can stage midpalatal suture maturation from CBCT yet. Key sources: • FDA — https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea • Eli Lilly — https://investor.lilly.com/news-releases/news-release-details/fda-approves-zepboundr-tirzepatide-first-and-only-prescription • AASM/AADSM — https://aasm.org/aasm-and-aadsm-issue-new-joint-clinical-practice-guideline-for-oral-appliance-therapy/ Episode 6061 — myweirdprompts.com/n/6061 (permanent short link: myweirdprompts.com/382183)